3.8 Article

Enhanced recovery after microvascular reconstruction in head and neck cancer - A prospective study

期刊

JPRAS OPEN
卷 34, 期 -, 页码 103-113

出版社

ELSEVIER
DOI: 10.1016/j.jpra.2022.08.001

关键词

Enhanced recovery after surgery; ERAS; Head and neck cancer; Head and neck reconstruction; Head and neck surgery; Microsurgery; Oral cavity cancer; Oral cavity squamous cell carcinoma; Perioperative care; Reconstructive surgery

类别

资金

  1. Concordiafonden

向作者/读者索取更多资源

This study presents the results of using an enhanced recovery after surgery (ERAS) protocol for microvascular reconstruction in patients with head and neck cancer. The study found that using the ERAS protocol resulted in shorter hospital stay, shorter time to ambulation, shorter time to removal of nasogastric tube, and fewer tracheostomies performed. There were no differences in complications, flap survival, or 30-day re-admissions between the two groups.
Objectives: Patients undergoing microvascular reconstruction after head and neck cancer typically have several comorbidities, and the procedures are often followed by complications and prolonged hospitalization. Consequently, the application of enhanced recovery after surgery (ERAS) for these patients undergoing microvascular reconstruction has gained attention in recent years. ERAS is a periand postoperative care concept that has repeatedly shown beneficial results for a wide variety of surgical procedures, including microvascular reconstruction. This study presents the results after the introduction of our ERAS protocol for head and neck cancer reconstruction. Methods: We prospectively treated 30 consecutive patients according to our ERAS protocol from June 2019 to December 2020 and compared the results of the treated patients with those of patients treated with our traditional recovery after surgery (TRAS) protocol. We are based on our ERAS protocol on the following core elements of recovery: improved patient information, goal-directed fluid therapy, minimally invasive surgery, opioid-sparing multimodal analgesia, early ambulation, and pre-defined functional discharge criteria. Results: The baseline characteristics of the groups were comparable. The ERAS group had a significantly shorter length of stay (13.1 vs. 20.3 days, p < 0.001), significantly shorter time to ambulation (3.0 days vs. 6.4 days, p < 0.001), shorter time to removal of nasogastric tube (13.3 days vs. 22.7 days, p = 0.05), and fewer tracheostomies performed (10% vs. 90%, p < 0.001). There were no differences in complications, flap survival, or 30-day re-admissions between the two groups. Conclusion: The introduction of ERAS in patients with head and neck cancer undergoing microvascular reconstruction seems safe and results in improved recovery. Level of evidence: 3 (c) 2022 The Author(s). Published by Elsevier Ltd on behalf of British Association of Plastic, Reconstructive and Aesthetic Surgeons.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

3.8
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据